Song Xin, Zhang Shidong, Tian Run, Zheng Chuanjun, Xu Yuge, Wang Tianxian, Bei Chunhua, Zhang Huixia, He Xiao, Zhu Xiaonian, Tan Shengkui
Department of Epidemiology and Health Statistics, Guilin Medical University, Guilin, Guangxi, China.
Open Med (Wars). 2021 Jan 28;16(1):217-223. doi: 10.1515/med-2021-0221. eCollection 2021.
CKLF Like Marvel Transmembrane Domain Containing 1 (CMTM1) plays a role in breast cancer and lung cancer, but studies on the occurrence and development of CMTM1 in hepatocellular carcinoma (HCC) have not been reported.
The Cancer Genome Atlas (TCGA) database and immunohistochemistry (IHC) were used to detect CMTM1 expression in HCC tissues. The relationship between CMTM1 expression and the clinicopathological characteristics of HCC patients was analyzed by chi-square test, and the relationship between CMTM1 expression and the prognosis of HCC patients was tested by the Kaplan-Meier model.
Bioinformatics analysis showed that the mRNA expression of CMTM1 was upregulated in HCC tissues, and low expression of CMTM1 is associated with longer disease-free survival in patients with HCC. Similarly, the survival time of HCC patients in CMTM1 high expression group was significantly shorter than that in CMTM1 low expression group. IHC detection indicated that CMTM1 protein was highly expressed in both HCC and adjacent non-tumor tissues, with a positive expression in 84% (63/75) of HCC tissues and 89.3% (67/75) of adjacent non-tumor tissues. Moreover, CMTM1 expression was related to family history and TNM stage of HCC patients ( < 0.05), but had no relationship with other clinicopathological characteristics. The survival analysis based on IHC results showed that the prognosis of HCC patients in CMTM1 negative group was significantly poorer than that in CMTM1 positive group ( < 0.05).
CMTM1 has a high expression in HCC tissues and is related to the prognosis of HCC patients.
含CKLF样MARVEL跨膜结构域蛋白1（CMTM1）在乳腺癌和肺癌中发挥作用，但CMTM1在肝细胞癌（HCC）发生发展中的研究尚未见报道。
利用癌症基因组图谱（TCGA）数据库和免疫组织化学（IHC）检测HCC组织中CMTM1的表达。采用卡方检验分析CMTM1表达与HCC患者临床病理特征的关系，用Kaplan-Meier模型检验CMTM1表达与HCC患者预后的关系。
生物信息学分析显示，CMTM1的mRNA表达在HCC组织中上调，CMTM1低表达与HCC患者更长的无病生存期相关。同样，CMTM1高表达组HCC患者的生存时间明显短于CMTM1低表达组。IHC检测表明，CMTM1蛋白在HCC及癌旁非肿瘤组织中均高表达，在84%（63/75）的HCC组织和89.3%（67/75）的癌旁非肿瘤组织中呈阳性表达。此外，CMTM1表达与HCC患者的家族史和TNM分期有关（P<0.05），但与其他临床病理特征无关。基于IHC结果的生存分析显示，CMTM1阴性组HCC患者的预后明显差于CMTM1阳性组（P<0.05）。
CMTM1在HCC组织中高表达，与HCC患者的预后有关。
